Kezar to discontinue mid-stage trial for lupus treatment

(Reuters) – Kezar Life Sciences said on Thursday it would terminate its mid-stage trial studying its experimental drug in patients with active lupus nephritis and focus on the development of the drug in autoimmune hepatitis.

(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)